右啡烷

**右啡烷**
臨床資料
其他名稱	DXO, Dextrorphanol
ATC碼	未分配;
法律規範狀態
法律規範	美：Unscheduled[1];
识别
	IUPAC命名法 (+)-17-methyl-9a,13a,14a-morphinan-3-ol; ;
CAS号	125-73-5
PubChem CID	5360697;
ChemSpider	10489895 ;
UNII	04B7QNO9WS;
ChEMBL	ChEMBL1254766 ;
CompTox Dashboard (EPA)	DTXSID301014178 ;
ECHA InfoCard	100.004.323
化学
化学式	C17H23NO
摩尔质量	257.38 g·mol−1
3D模型（JSmol）	交互式图像;
	SMILES CN1CC[C@@]23CCCC[C@@H]2[C@@H]1Cc4c3cc(O)cc4;
	InChI InChI=1S/C17H23NO/c1-18-9-8-17-7-3-2-4-14(17)16(18)10-12-5-6-13(19)11-15(12)17/h5-6,11,14,16,19H,2-4,7-10H2,1H3/t14-,16+,17+/m1/s1 ; Key:JAQUASYNZVUNQP-PVAVHDDUSA-N ;

右啡烷（Dextrorphan，DXO）是一種吗啡類的精神药物，具有鎮咳與止咳，或作為解离性致幻剂的作用，也是外消旋嗎汎的右旋对映体，另一個左旋对映体則是左旋嗎汎。右啡烷是右美沙芬由CYP2D6酶经O-脱甲基（O-demethylated）而生成的，作為一种NMDA拮抗剂，右啡烷可产生右美沙芬所帶來的精神效應。[2]

藥理學

藥效學

右啡烷[3][4][5][6]
位置	K_i (nM)	對象	引用
NMDAR (MK-801)	486–906	鼠	[4]
σ₁	118–481	鼠	[4]
σ₂	11,325–15,582	鼠	[4]
MOR	420 >1,000	鼠人	[4][7]
DOR	34,700	鼠	[4]
KOR	5,950	鼠	[4]
SERT	401–484	鼠	[4]
NET	≥340	鼠	[4]
DAT	>1,000	鼠	[4]
5-HT_1A	>1,000	鼠	[4]
5-HT_1B_/_1D	54% at 1 μM	鼠	[4]
5-HT_2A	>1,000	鼠	[4]
α₁	>1,000	鼠	[4]
α₂	>1,000	鼠	[4]
β	35% at 1 μM	鼠	[4]
D₂	>1,000	鼠	[4]
H₁	95% at 1 μM	鼠	[4]
mAChRs	100% at 1 μM	鼠	[4]
nAChRs	1,300–29,600 (IC₅₀)	鼠	[4]
VDSCs	ND	ND	ND
除非另加说明，否则以上所示数值均为K_i(nM)。数值越小，說明药物与该位点的结合力越强。

右啡烷的药理作用類似於右美沙芬。不过，右啡烷作为NMDA受体拮抗剂的效力要强得多，作为SRI的活性也低得多。不過右啡烷仍保留了右美沙芬作为NRIs時的活性。[8]並且其对阿片受体的亲和力也較右美沙芬强，且高剂量下更強。

药代动力学

右啡烷的生物半衰期長於其母体化合物，因此在重复服用正常剂量的右美沙芬制剂后容易在血液中蓄积。其還會被CYP3A4进一步转化为3-羥基嗎啡喃或被葡萄醣醛酸化。[9]

研究

右啡烷曾被开发用于治疗中风，也已进行了II期临床试验，但开发工作已经中止。[10]

參考文獻

Bensinger, Peter. (PDF). NARA. October 1, 1976 [June 26, 2023]. （原始内容存档 (PDF)于2023-06-27）.
Zawertailo LA, Kaplan HL, Busto UE, Tyndale RF, Sellers EM. . Journal of Clinical Psychopharmacology. August 1998, 18 (4): 332–337. PMID 9690700. doi:10.1097/00004714-199808000-00014.
Roth BL, Driscol J. . Psychoactive Drug Screening Program (PDSP). University of North Carolina at Chapel Hill and the United States National Institute of Mental Health. [14 August 2017]. （原始内容存档于2023-01-01）.
Nguyen L, Thomas KL, Lucke-Wold BP, Cavendish JZ, Crowe MS, Matsumoto RR. . Pharmacol. Ther. 2016, 159: 1–22. PMID 26826604. doi:10.1016/j.pharmthera.2016.01.016.
Werling LL, Keller A, Frank JG, Nuwayhid SJ. . Exp. Neurol. 2007, 207 (2): 248–57. PMID 17689532. S2CID 38476281. doi:10.1016/j.expneurol.2007.06.013.
Taylor CP, Traynelis SF, Siffert J, Pope LE, Matsumoto RR. . Pharmacol. Ther. 2016, 164: 170–82. PMID 27139517. doi:10.1016/j.pharmthera.2016.04.010 .
Raynor K, Kong H, Mestek A, Bye LS, Tian M, Liu J, Yu L, Reisine T. . J. Pharmacol. Exp. Ther. 1995, 272 (1): 423–8. PMID 7815359.
Pechnick RN, Poland RE. . The Journal of Pharmacology and Experimental Therapeutics. May 2004, 309 (2): 515–522. PMID 14742749. S2CID 274504. doi:10.1124/jpet.103.060038.
Yu A, Haining RL. . Drug Metabolism and Disposition. November 2001, 29 (11): 1514–20 [2023-10-01]. PMID 11602530. （原始内容存档于2020-03-12）.
. [2023-10-01]. （原始内容存档于2021-07-05）.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.

[1] Bensinger, Peter. (PDF). NARA. October 1, 1976 [June 26, 2023]. （原始内容存档 (PDF)于2023-06-27）.

[2] Zawertailo LA, Kaplan HL, Busto UE, Tyndale RF, Sellers EM. . Journal of Clinical Psychopharmacology. August 1998, 18 (4): 332–337. PMID 9690700. doi:10.1097/00004714-199808000-00014.

[PDSP-3] Roth BL, Driscol J. . Psychoactive Drug Screening Program (PDSP). University of North Carolina at Chapel Hill and the United States National Institute of Mental Health. [14 August 2017]. （原始内容存档于2023-01-01）.

[pmid26826604-4] Nguyen L, Thomas KL, Lucke-Wold BP, Cavendish JZ, Crowe MS, Matsumoto RR. . Pharmacol. Ther. 2016, 159: 1–22. PMID 26826604. doi:10.1016/j.pharmthera.2016.01.016.

[pmid17689532-5] Werling LL, Keller A, Frank JG, Nuwayhid SJ. . Exp. Neurol. 2007, 207 (2): 248–57. PMID 17689532. S2CID 38476281. doi:10.1016/j.expneurol.2007.06.013.

[pmid27139517-6] Taylor CP, Traynelis SF, Siffert J, Pope LE, Matsumoto RR. . Pharmacol. Ther. 2016, 164: 170–82. PMID 27139517. doi:10.1016/j.pharmthera.2016.04.010 .

[pmid7815359-7] Raynor K, Kong H, Mestek A, Bye LS, Tian M, Liu J, Yu L, Reisine T. . J. Pharmacol. Exp. Ther. 1995, 272 (1): 423–8. PMID 7815359.

[8] Pechnick RN, Poland RE. . The Journal of Pharmacology and Experimental Therapeutics. May 2004, 309 (2): 515–522. PMID 14742749. S2CID 274504. doi:10.1124/jpet.103.060038.

[DXMdualprobe-9] Yu A, Haining RL. . Drug Metabolism and Disposition. November 2001, 29 (11): 1514–20 [2023-10-01]. PMID 11602530. （原始内容存档于2020-03-12）.

[AdisInsight-10] . [2023-10-01]. （原始内容存档于2021-07-05）.